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Abstract. The objective of this report was to study the
elimination pharmacokinetics of iodixanol in children.
Iodixanol (VISIPAQUE®, Nycomed Inc., Wayne, PA,
USA) is a new iso-osmolar iodinated radiocontrast agent.
We hypothesized that elimination of this agent would be
dependent on age-related differences in renal clearance.
Seven centers enrolled 43 patients. Cardiac catheteriza-
tion was performed in 41 patients and cranial computed
tomography in 2. Patients were entered into 5 age
groups: newborn to <2 months, 2 to <6 months, 6 months
to <1 year, 1 to <3 years, and 3 to#12 years. Plasma
samples were obtained before and at 4 time periods after
completion of iodixanol injection: 0.75–1.25 hours, 2–4
hours, 8–12 hours, and 16–32 hours. Plasma concentra-
tions of iodixanol were determined using high perfor-
mance liquid chromatography. The primary pharmaco-
kinetic endpoint was the terminal elimination rate con-
stant (kel). Data were complete for 40 patients, showing
meankel significantly lower in newborn to <2-month-old
patients vs older patients: (h−1, mean ± standard devia-
tion [SD]): newborn to <2 months 0.185 ± 0.060, 2 to <6
months, 0.256 ± 0.046, 6 months to <1 year 0.299 ±
0.042, 1 to <3 years 0.322 ± 0.058, and 3 to#12 years
0.307 ± 0.071; with increasing age, excretion is more
rapid, as shown by each age group’s elimination half-life
(t1/2 b) (h) 4.14 ± 1.41, 2.79 ± 0.55, 2.36 ± 0.37, 2.23 ±
0.51, and 2.36 ± 0.52, respectively. Iodixanol has elimi-
nation in children >6 months of age that is comparable to
normal adults. Prolonged elimination in children <6
months of age is related to renal immaturity.
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Iodixanol (VISIPAQUE® Injection) is a dimeric, nonionic
radiographic contrast medium, which, unlike traditional
ionic and nonionic contrast agents, has an osmolality
equal to blood. Iodixanol may offer advantages over con-
ventional hypertonic media, particularly in children with
renal and myocardial immaturity. The elimination of io-
dixanol in children has not been previously studied.
Clearance of contrast agents in adults occurs primar-
ily by renal elimination [9]. Patients with renal impair-
ment have delayed elimination and prolonged plasma
levels of contrast agents, including iodixanol, that are
linearly related to the glomerular filtration rate (GFR)
[5]. We hypothesized that the same would be true of
infants (aged 0–6 months), in whom normal renal func-
tion, as assessed by GFR, is less than adult values [8];
this would result in slower renal elimination of iodixanol
and lower terminal elimination rate constants (kel). This
would also show thatkel in older children would be simi-
lar to those reported for adults.
We performed a multicenter study to test this hy-
pothesis by determining the pharmacokinetic profile of
iodixanol in pediatric patients undergoing contrast-
enhanced diagnostic procedures.
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Materials and Methods
Study Centers
Seven pediatric centers participated: the University of Alabama at Bir-
mingham, Birmingham, AL, USA; CS Mott Children’s Hospital, Ann
Arbor, MI, USA; the University of Florida, Gainesville, FL, USA; the
Deborah Heart and Lung Center, Browns Mills, NJ, USA; Children’s
Hospital of Michigan (the Division of Pediatric Cardiology and the
Department of Pediatric Imaging operated as separate entities), Detroit,
MI, USA; and the University of Kansas Medical Center, Kansas City,
KS, USA.
Authors JAJ and PAM were employed by the study sponsor,
Nycomed, Inc. Other than the support provided by Nycomed, Inc. to
each center for conducting this study, the other authors have no com-
mercial interest in Nycomed, Inc.
Patients
Newborn infants ($36 weeks gestational age and$2000 g body
weight at time of enrollment) to children#12 years of age, referred for
an iodinated contrast-enhanced intravascular diagnostic procedure,
were eligible. Patients undergoing interventional procedures (biopsy,
balloon atrial septostomy, coil embolization, balloon dilation of aortic
or pulmonary valves, or coarctation) were included.
Prior approval by each center’s human subjects Institutional Re-
view Board was received, and written informed consent was obtained
from the parent or legal representative of each patient. No incentives




carboxamide]) was supplied by Nycomed Inc. (Wayne, PA, USA) as a
652 mg/ml solution, equivalent to 320 mgI/ml. Patients received io-
dixanol in identical fashion to approved contrast agents, without modi-
fication of dose or administration method. Pharmacokinetic samples
were obtained at baseline (preinjection) and at four time periods after
injection: 0.75–1.25 hours, 2–4 hours, 8–12 hours, and 16–32 hours.
Blood samples were collected in potassium oxalate/sodium fluoride
Vacutainer™ tubes (Becton Dickinson, Rutherford, NJ, USA) and were
spun immediately. The plasma was separated, was frozen to#−20°C,
and was shipped to Nycomed Inc. for analysis.
Iodixanol Assay
Plasma iodixanol assays were performed by Nycomed Inc. using size-
exclusion, high-performance liquid chromatography with ultraviolet
detection [4]. The assays were modified as follows: reference standard
concentrations ranged from 1.5–1000mg/ml. The assay was validated
to a minimum quantifiable level of 1.5mg/mL. Triplicate quality-
control samples at three concentrations were included in each analytical
run.
Pharmacokinetic Analysis
Based on data for adults, the concentration vs time curve is best esti-
mated by a one-compartment model with a first-order elimination rate.
In adults, the distribution phase for intravascular administration is of
small magnitude and occurs rapidly, so this term was assumed to be
zero. The terminal elimination rate constant (kel) was computed by
linear regression of the natural logarithm of the plasma iodixanol con-
centration as a function of time:
c(t) 4 c0e
−kelt
where c(t) is the concentration at time t, c0 is the concentration at time
0, and t is the time after the end of the administration of iodixanol
(defined as time zero). Preinjection sample times were set to zero and
actual times were used for all postinjection samples. Elimination half-
life was calculated as t1/2 4 0.693/kel.
Study Design and Statistical Analysis
Male and female patients were enrolled by age into 5 age groups: birth
to <2 months, 2 to <6 months, 6 to <12 months, 1 to <3 years, and 3
to # to 12 years. Analysis of interinstitutional differences was not
performed because no more than 10 patients were enrolled per center.
The relationship betweenkel and age for individual patients was
modeled using a linear-plateau model [2, 6] (details available from the
authors).kel was analyzed for dose (continuous) and age-group (class)
effects using a general linear model, because the dose of iodixanol
varied from patient to patient in each group. Sample size was selected
with the expectation thatkel in the youngest and oldest age groups
could be distinguished from one another, based on published renal
elimination rates [8]. We chose age-group intervals corresponding to
these published data. Statistical tests were performed with a level of
significance set at 0.05.
Results
Patient Demographics
Forty-three patients were enrolled, ranging from 2–10
patients per center. All patients completed the trial. The
data from 40 patients were used in the pharmacokinetic
analyses. Two patients had incomplete pharmacokinetic
sampling data; their pharmacokinetic data were ex-
cluded. Two additional patients were enrolled as replace-
ments in the same respective age groups. A third patient
was excluded from pharmacokinetic analyses because of
abnormal renal function before participation in the trial.
One patient, entered in error as the ninth patient in the 6
month to <1 year of age group, was included in the
analyses.
The majority of the patients were boys (63%) and
Caucasian (60%); the median age was 0.56 years (range
0–10.4) and median body weight 6.6 kg (range 3–40)
(Table 1). The majority of patients (56%) had more than
one diagnosis; the most common was ventricular septal
defect (40%), followed by patent ductus arteriosus
(19%), aortic stenosis (16%), tetralogy of Fallot (14%),
atrial septal defect (14%), pulmonary stenosis (14%) and
aortic hypoplasia (12%).
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Type of Study, Dose, and Mode of Iodixanol Delivery
Two patients who underwent head and/or neck CT scan-
ning received intravenous iodixanol, whereas all other
patients had injection during angiocardiography. The
mean (±SD) dose of iodixanol 320 mgI/ml was 1.49 ±
0.75 gI/kg and the mean total volume was 4.67 ± 2.34
ml/kg. Median and range of dose data are presented in
Table 1. The mean duration of the procedure was 30 ± 29
minutes (range 0–102) and the median number of injec-
tions was 2 (range 1–8).
The median dose per kg of iodixanol 320 mgI/ml
and median total volume per kg was similar for the four
patient groups less than 3 years of age. The median dose
per kg and median total volume per kg for patients$3
years of age were approximately half that for patients <3
years of age (Table 1). Patients <3 years of age received
an average of approximately 3 injections per patient;
patients$3 years of age averaged 1.6 injections per pa-
tient.
Concurrent Medications and Drug Interaction
Concurrent medications (from 24 hours before the start
of the radiographic procedure until up to 32 hours postin-
jection) were received by 36 (84%) of patients; the ma-
jority (63%) received cardiovascular medications (e.g.,
digoxin, diuretics). Premedication/procedural medica-
tions were received by all patients. These medications
included sedatives, anesthetics, and analgesics by 98% of
patients, cardiovascular drugs (e.g., inotropes, vasodila-
tors, prostaglandin) by 74% of patients, and antithrom-
botic drugs and/or intravenous solutions by 61%. No
drug interactions were identified.
Pharmacokinetics
The highest plasma iodixanol levels were found during
the first sampling period (0.75–1.25 hours) after injec-
tion, and ranged from 970–11,102mg/ml, with a median
of 4718mg/ml.
The meankel was significantly lower in the newborn
to <2 month age group than in any of the three oldest age
groups (p # 0.0001). Meankel for the 2 to <6 month age
group (0.256/h) was intermediate between that of the
newborn to <2 month age group (0.185/h) and those of
older patients (0.299/h to 0.322/h). Total dose was not a
significant independent variable (p 4 0.08). The mean
kel in the youngest age group (0.185/h) represented ap-
proximately 55% of the adult meankel value of 0.336/h
[1] (Table 2).
A segmented linear regression model (Fig. 1)
showed increasingkel from birth to approximately age
0.55 years (95% CI: 0.36 to 0.75 years). The model also
showed estimatedkel for patients over 0.55 years as
0.313/h (corresponding to an elimination t1/2 of 2.21 h).
The predictedkel at birth was 0.169/h (95% CI: 0.131 to
0.208/h, or a t1/2 of 4.1 h). This model accounted for
almost 97% of the observed age-related variability inkel.
Laboratory Data
Preinjection serum creatinine values ranged from 0.1–1.1
mg/dl and did not correlate with age. Renal function was
considered normal-for-age in all but the one patient who
was excluded from the analyses. One day postinjection,
2 patients had increases in serum creatinine to levels
above the 95% CI for age, yet no creatinine value ex-
ceeded 1.1 mg/dl in any patient. No patient showed clini-
cal evidence of renal insufficiency, except for the patient
excluded because of prexisting renal insufficiency. No
patient had evidence of structural renal abnormalities.
Discussion
Pharmacokinetic data regarding contrast media in chil-
dren is limited [3, 7]. However, the pharmacokinetic pro-
Table 1.Patient demographics and iodixanol dose
Patient group <2 months 2 to <6 months 6 to <12 months 1 to <3 years 3 to#12 years All patients
Number of patients 8 9 10 8 8 43
Age 2 days 0.29 years 0.67 years 1.84 years 6.46 years 0.56 years
12 hours–59 days 0.17–0.41 years 0.51–0.90 years 1.06–2.96 years 3.16–10.41 years 0–10.41 years
Weight kg 4 4.9 7.3 11.3 19.1 6.6
3–5 3–6 6–11 7–14 14–40 3–40
Dose gI/kga 1.5 1.5 1.3 1.2 0.8 1.3
0.7–3.2 1.0–2.9 0.8–2.7 0.3–3.0 0.3–1.3 0.3–3.2
Dose volume ml/kg 4.8 4.8 4.2 3.9 2.4 4.0
2.0–10.0 3.3–9.0 2.4–8.5 1.1–9.2 1.0–4.0 1.0–10.0
Number of injections 2.5 3 3 3 2 2
1–5 2–5 1–4 1–8 1–2 1–8
Data are median and range.
a g iodine/kg body weight.
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files of several iodinated radiographic contrast agents are
well described in adults [5, 9, 10, 11]. In a single-dose
study of iodixanol administered to 40 healthy adult men
[9], approximately 97% of iodixanol was excreted un-
changed in the urine within 24 hours. Elimination was
independent of dose and was similar to other nonionic
agents.
We found iodixanol elimination rates in children
older than 6 months (t1/2 b 2.32 hours), similar to those
reported for healthy adults (t1/2 b 2.05 hours) [9]. In
adults with renal impairment, renal elimination of iodixa-
nol and iohexol is via glomerular filtration only [5]. In
our patients <2 months of age, we demonstrated pro-
longed clearance of iodixanol. This corresponds to this
age group’s lower, yet normal-for-age, GFR as published
[8]. Infants in the 2 to 6-month age group had elimination
intermediate between our youngest infants and patients
older than 6 months. Our data confirm our hypothesis of
an age-dependent renal elimination of iodixanol.
Our findings suggest that in pediatric patients, the
renal elimination of iodixanol should be similar to con-
ventional contrast media. We speculate that safety of
iodixanol in children should not be related to its elimi-
nation pharmacokinetics.
In adult patients, clinical trials of iodixanol demon-
strated similar efficacy, safety, and pharmacokinetics as
compared with other nonionic agents [1]. Iodixanol so-
lution is hypotonic at iodine concentrations adequate for
imaging. Sodium and calcium are added to obtain a
plasma-isoosmolal solution. The presence of sodium and
calcium ions in iodixanol, and its osmolality, may result
in fewer side effects. However, higher viscosity, as com-
pared with other agents, may be a relative disadvantage.
More experience is needed in infants and children to
determine if the chemical properties of iodixanol confer
safety advantages over conventional nonionic agents.
Study Limitations
Our study is limited by the absence of a comparison
group of pediatric patients receiving a conventional, non-
ionic agent. Although our patients had normal indicators
of renal function for age, we did not measure creatinine
clearance or GFR. The performance of these studies in
pediatric patients is no less problematic today than when
the widely accepted renal clearance data, upon which we
based our hypotheses, were first measured decades ago
[8]. It is possible that concurrent drugs could have altered
iodixanol clearance by altering renal blood flow (e.g.,
inotropes) or by a direct effect on renal filtration (e.g.,
prostaglandin). However, our patient numbers were too
small for analysis of a specific drug’s possible effect.
Although we found no relation of iodixanol dose to
elimination rate, it is possible that a dose effect might be
evident in the youngest patients, given a larger sample
size.
Fig. 1. Analysis ofkel vs age for
iodixanol. The terminal elimination
rate constant,kel (h
−1) is plotted
against age (years) for each indi-
vidual patient (closed dots). Using a
segmented linear regression model,
kel increases with increasing age
from birth to a value of 0.313/h at
0.55 years, according to the regres-
sion kel 4 0.169 + 0.26 (age); at
ages older than 0.55 years,kel is
relatively constant, represented by a
horizontal line with y-intercept of
0.313/h.
Table 2. Iodixanol elimination rate constant (kel) and elimination half-




Mean SD Mean SD
Newborn to <2 months 8 0.185 0.060 4.14 1.41
2 to <6 months 8 0.256 0.046 2.79 0.55
6 months to <1 year 9 0.299 0.042 2.36 0.37
1 to <3 years 7 0.322 0.058 2.23 0.51
3 to #12 years 8 0.307 0.071 2.36 0.52
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Conclusion
Our study demonstrates that iodixanol injection (320
mgI/ml), when used as a radiographic contrast agent in
pediatric patients undergoing angiography or CT scan-
ning, is eliminated in a fashion similar to that in adults.
The elimination is dependent on the age-related degree
of renal maturity.
Acknowledgments.We would like to acknowledge the valuable assis-
tance of Connie S. Nixon, RN, Tandaw E. Samdarshi, MD, and Ronald
W. Palmer, BS, MS. Funded in part by Nycomed Inc., 466 Devon Park
Drive, Wayne, PA 19087-8630, USA.
References
1. Fountaine H, Harnish P, Andrew E, Grynne B (1996) Safety, tol-
erance, and pharmacokinetics of iodixanol injection, a nonionic,
isosmolar, hexa-iodinated contrast agent.Acad Radiol 3:S475–
S484
2. Hudson DJ (1966) Fitting segmented curves whose join points
have to be estimated.J Amer Statist Ass. 61: 097–1129
3. Klingmüller V, Brockmeier D, Schuster W, von Hattingberg HM
(1983) Pharmakokinetische aspekte der ausscheidungsurographie
im kindesalter. [Pharmacokinetic aspects of excretory urography in
children].ROFO Fortschr Geb Rontgenstr Nuklearmed 138:316–
322
4. Nomura H, Teshima E, Hakusui H (1991) Simple isocratic high-
performance liquid chromatographic method for measurement of
iodixanol in human plasma.J Chromatogr 572:333–338
5. Nossen JO, Jakobsen JA, Kjaersgaard P, Andrew E, Jacobsen PB,
Berg KJ (1995) Elimination of the non-ionic x-ray contrast media
iodixanol and iohexol in patients with severely impaired renal
function.Scand J Clin Lab Invest 55:341–350
6. Ralston ML, Jennrich RI (1978) Dud, a derivative-free algorithm
for nonlinear least squares.Technometrics 20:7–14
7. Stake G, Monclair T (1991) A single plasma sample method for
estimation of the glomerular filtration rate in infants and children
using iohexol, I: establishment of a body weight-related formula
for the distribution volume of iohexol.Scand J Clin Lab Invest
51:335–342
8. Stewart CF, Hampton EM (1987) Effect of maturation on drug
disposition in pediatric patients.Clin Pharm 6:548–564
9. Svaland MG, Haider T, Langseth-Manrique K, Andrew E, Hals PA
(1992) Human pharmacokinetics of iodixanol.Invest Radiol 27:
130–133
10. Svaland MG, Kolmannskog PE, Lillevold PE, Nordal KP, Ressem
L, Berg KJ (1992) Pharmacokinetics of iopental in patients with
chronic renal failure.Acta Radiologica 33:482–484
11. Thomsen HS, Vestergaard A, Nielsen SL, Fogh-Andersen N, Gol-
man K, Dorph S (1991) Renal clearance of an ionic high-osmolar
and a nonionic low-osmolar contrast medium.Invest Radiol 26:
564–568
227Johnson et al.: Iodixanol Pharmacokinetics in Children
